知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.017 秒)

    Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety
    2.
    发明授权
    Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety 失效
    具有附着的靶结合部分和动脉粥样硬化斑块相互作用部分的脂质体

    公开(公告)号：US06379699B1

    公开(公告)日：2002-04-30

    申请号：US09407705

    申请日：1999-09-28

    申请人： Jorma Virtanen ,  Sinikka Virtanen

    发明人： Jorma Virtanen ,  Sinikka Virtanen

    IPC分类号： A61K9127

    CPC分类号： A61K9/1271 ,  A61K38/00 ,  A61K47/56 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6839 ,  A61K47/6911 ,  C07K16/1063 ,  C07K19/00 ,  C07K2319/00 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  Y10S530/812 ,  Y10S977/907

    摘要： Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or antibody at a site of infection or tumor, and another effector molecule is a therapeutic molecule such as an enzyme or drug. The joining component may be a liposome, protein or an organic polymer (including a dendrimer type polymer), and may be of sufficient length and/or flexibility to permit the therapeutic molecule to physically interact with the target at the same time as the binding molecule. Supramolecules are formed containing at least two supramolecular component molecules that contain an effector molecule and a nucleic acid chain. A nucleic acid chain on a component molecule is complementary to a nucleic acid chain on another component molecule to enable binding of the component molecules of the supramolecule by the formation of double stranded nucleic acid chains between complementary chains. A targetable antiviral supramolecule is prepared containing spectrin as the joining component. The binding molecule can be an antibody specific for an antigen on a viral particle and the therapeutic molecule can be an enzyme capable of destroying infectivity of the virus by hydrolysis of viral coat protein or viral lipid. A targeting moiety that binds to low density lipoprotein or artherosclerotic plaque and a therapeutic moiety that interacts with artherosclerotic plaque are attached to a liposome for treating atherosclerosis.

    摘要翻译： 制备的复合物含有通过接合组分彼此连接的两个或更多个不同的效应分子。 一个效应分子是结合分子，例如抗体或Fc受体，其在感染或肿瘤部位与分子靶标如病毒或抗体结合，另一个效应分子是诸如酶或药物的治疗分子。 连接组分可以是脂质体，蛋白质或有机聚合物（包括树枝状聚合物类型的聚合物），并且可以具有足够的长度和/或柔性，以允许治疗性分子在与结合分子同时与物质相互作用 。 形成含有至少两个含有效应分子和核酸链的超分子组分分子的超分子。 组分分子上的核酸链与另一组分分子上的核酸链互补，以通过互补链之间的双链核酸链的形成来结合超分子的组分分子。 制备可靶向的抗病毒超分子，其包含作为连接组分的血影蛋白。 结合分子可以是对病毒颗粒上的抗原特异的抗体，并且治疗分子可以是能够通过病毒外壳蛋白或病毒脂质的水解来破坏病毒感染性的酶。 结合低密度脂蛋白或动脉粥样硬化斑块的靶向部分和与动脉粥样硬化斑块相互作用的治疗部分附着于用于治疗动脉粥样硬化的脂质体。

    Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
    3.
    发明授权
    Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin 失效
    含有靶结合分子和结合血影蛋白的治疗分子的抗病毒超分子

    公开(公告)号：US5997861A

    公开(公告)日：1999-12-07

    申请号：US627695

    申请日：1996-03-29

    申请人： Jorma Virtanen ,  Sinikka Virtanen

    发明人： Jorma Virtanen ,  Sinikka Virtanen

    IPC分类号： C12N15/09 ,  A61K9/127 ,  A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K48/00 ,  A61P9/10 ,  A61P31/12 ,  A61P43/00 ,  C07K14/73 ,  C07K16/10 ,  C07K19/00 ,  C12N11/18 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  A61K38/51 ,  C12N11/02

    CPC分类号： A61K47/48369 ,  A61K47/48169 ,  A61K47/484 ,  A61K47/48523 ,  A61K47/48815 ,  A61K9/1271 ,  C07K16/1063 ,  C07K19/00 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  A61K38/00 ,  C07K2319/00 ,  Y10S530/812 ,  Y10S977/907

    摘要： Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc receptor that binds to a molecular target such as a virus or antibody at a site of infection or tumor, and another effector molecule is a therapeutic molecule such as an enzyme or drug. The joining component may be a liposome, protein or an organic polymer (including a dendrimer type polymer), and may be of sufficient length and/or flexibility to permit the therapeutic molecule to physically interact with the target at the same time as the binding molecule. Supramolecules are formed containing at least two supramolecular component molecules that contain an effector molecule and a nucleic acid chain. A nucleic acid chain on a component molecule is complementary to a nucleic acid chain on another component molecule to enable binding of the component molecules of the supramolecule by the formation of double stranded nucleic acid chains between complementary chains. A targetable antiviral supramolecule is prepared containing spectrin as the joining component. The binding molecule can be an antibody specific for an antigen on a viral particle and the therapeutic molecule can be an enzyme capable of destroying infectivity of the virus by hydrolysis of viral coat protein or viral lipid.

    摘要翻译： 制备的复合物含有通过接合组分彼此连接的两个或更多个不同的效应分子。 一个效应分子是结合分子，例如抗体或Fc受体，其在感染或肿瘤部位与分子靶标如病毒或抗体结合，另一个效应分子是诸如酶或药物的治疗分子。 连接组分可以是脂质体，蛋白质或有机聚合物（包括树枝状聚合物类型的聚合物），并且可以具有足够的长度和/或柔性，以允许治疗性分子在与结合分子同时与物质相互作用 。 形成含有至少两个含有效应分子和核酸链的超分子组分分子的超分子。 组分分子上的核酸链与另一组分分子上的核酸链互补，以通过互补链之间的双链核酸链的形成来结合超分子的组分分子。 制备可靶向的抗病毒超分子，其包含作为连接组分的血影蛋白。 结合分子可以是对病毒颗粒上的抗原特异的抗体，并且治疗分子可以是能够通过病毒外壳蛋白或病毒脂质的水解来破坏病毒感染性的酶。

    Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids
    4.
    发明授权
    Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids 失效
    超分子治疗结合分子复合物

    公开(公告)号：US06814964B2

    公开(公告)日：2004-11-09

    申请号：US10105211

    申请日：2002-03-25

    申请人： Jorma Virtanen ,  Sinikka Virtanen

    发明人： Jorma Virtanen ,  Sinikka Virtanen

    IPC分类号： A61K3843

    CPC分类号： A61K9/1271 ,  A61K38/00 ,  A61K47/56 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6839 ,  A61K47/6911 ,  C07K16/1063 ,  C07K19/00 ,  C07K2319/00 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  Y10S530/812 ,  Y10S977/907

    摘要： A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector molecule covalently joined to a second nucleic acid, wherein the second nucleic acid has a region of at least partial complementarity to the first nucleic acid, wherein the first nucleic acid is in a base pairing relationship with the second nucleic acid and the first or second effector molecules are proteins, polypeptides, lipids or sugars. The supramolecule may further have a third supramolecule component which includes a third effector molecule covalently joined to a third nucleic acid, wherein the third nucleic acid has a region of at least partial complementary to the first nucleic acid or the second nucleic acid and wherein the third nucleic acid is in a base pairing relationship with the second nucleic acid or the first nucleic acid.

    摘要翻译： 超分子具有包含共价连接到第一核酸的第一效应分子的第一超分子组分和包含共价连接到第二核酸的第二效应分子的第二超分子组分，其中第二核酸具有至少部分的区域 与第一核酸的互补性，其中第一核酸与第二核酸具有碱基配对关系，第一或第二效应分子是蛋白质，多肽，脂质或糖。 超分子还可以具有第三超分子组分，其包括共价连接到第三核酸的第三效应分子，其中第三核酸具有与第一核酸或第二核酸至少部分互补的区域，并且其中第三核酸 核酸与第二核酸或第一核酸具有碱基配对关系。

    Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
    5.
    发明授权
    Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme 失效
    具有偶联的靶结合部分和水解酶的抗病毒脂质体

    公开(公告)号：US5718915A

    公开(公告)日：1998-02-17

    申请号：US424874

    申请日：1995-04-19

    申请人： Jorma Virtanen ,  Sinikka Virtanen

    发明人： Jorma Virtanen ,  Sinikka Virtanen

    IPC分类号： G01N33/531 ,  A61K9/127 ,  A61K31/70 ,  A61K38/00 ,  A61K38/46 ,  A61K47/48 ,  A61P9/10 ,  A61P31/12 ,  C07H21/00 ,  C07K14/73 ,  C07K16/00 ,  C07K16/10 ,  C07K17/00 ,  C07K19/00 ,  C12N15/09 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  C12N7/04 ,  C12N11/00

    CPC分类号： C07K16/1063 ,  A61K47/48169 ,  A61K47/48369 ,  A61K47/484 ,  A61K47/48523 ,  A61K9/1271 ,  C07K19/00 ,  C12N15/88 ,  C12Q1/68 ,  G01N33/535 ,  A61K38/00 ,  C07K2319/00 ,  Y10S977/728 ,  Y10S977/729 ,  Y10S977/754 ,  Y10S977/882 ,  Y10S977/898 ,  Y10S977/907

    摘要： Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. At least one of the effector molecules can bind to a target molecule and at least one of the other effector molecules has therapeutic properties. The joining component can be liposomes, proteins and organic polymers including dendrimer polymers, and can be of sufficient length and/or flexibility to permit the therapeutic effector molecule to interact with a target at the same time as the binding molecules. An antiviral liposome is prepared by coupling to a liposome outer surface a hydrolytic enzyme capable of digesting a viral component and a target-binding moiety which may be a polypeptide, glycoprotein or glycoprotein fragment having specificity for viruses such as HIV-1, influenza virus and hepatitis virus. The hydrolytic enzyme may be a glycosidase, phospholipase, lipase, cholesterol esterase, nuclease or protease. A second hydrolytic enzyme and target-binding moiety may also be present, and albumin may be coupled to the liposome surface. Within the liposome may be an internal hydrolytic enzyme capable of digesting a viral component.

    摘要翻译： 制备的复合物含有通过接合组分彼此连接的两个或更多个不同的效应分子。 至少一个效应分子可以结合靶分子，并且至少一个其它效应分子具有治疗性质。 连接组分可以是脂质体，蛋白质和包括树状聚合物聚合物的有机聚合物，并且可以具有足够的长度和/或柔性，以允许治疗效应分子与结合分子同时与靶相互作用。 通过将脂质体外表面与能够消化病毒组分的水解酶和靶结合部分（其可以是具有对HIV-1，流感病毒等病毒具有特异性的多肽，糖蛋白或糖蛋白片段）进行偶联来制备抗病毒脂质体， 肝炎病毒。 水解酶可以是糖苷酶，磷脂酶，脂肪酶，胆固醇酯酶，核酸酶或蛋白酶。 也可以存在第二水解酶和​​靶结合部分，并且白蛋白可以偶联到脂质体表面。 在脂质体内可以是能够消化病毒成分的内部水解酶。